All times shown are PDT (GMT-7) (San Francisco)

Displaying One Session

Abstract Sessions On-Demand Channel

Oral poster discussion session
Room
Abstract Sessions On-Demand Channel
Oral poster discussion session

Introduction

Room
Abstract Sessions On-Demand Channel
Oral poster discussion session

Time to viral rebound after interruption of modern antiretroviral therapies

Oral poster discussion session

Is DTG+3TC effective and safe in clinical practice? Evidence from real world data

Room
Abstract Sessions On-Demand Channel
Oral poster discussion session

Comparative efficacy and safety of a combination therapy of dolutegravir and lamivudine vs 3-drug antiretroviral regimens in treatment-naïve HIV-1 infected patients at 96 weeks: A systematic review and network meta-analysis

Room
Abstract Sessions On-Demand Channel
Oral poster discussion session

Switching to dolutegravir plus lamivudine (DTG+3TC) is non-inferior to and as safe as continuing standard triple antiretroviral therapy (TAR)

Room
Abstract Sessions On-Demand Channel
Oral poster discussion session

Optimizing the management of patients with virologic non-suppression

Oral poster discussion session

Conclusion

Room
Abstract Sessions On-Demand Channel